RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancy (RUNX1‑FPDMM): Comprehensive Research Report

1. Disease Information

Overview. RUNX1‑FPDMM (also called FPD/AML, familial platelet disorder with propensity to myeloid malignancy, or "hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1") is an autosomal dominant condition caused by heterozygous germline pathogenic variants in RUNX1. It is defined by (1) quantitative and qualitative platelet defects causing a bleeding diathesis and (2) a markedly elevated, lifelong risk of myeloid malignancy — principally myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with T‑ and B‑cell acute lymphoblastic leukemia also reported (GeneReviews, updated 2024–2025). It was first delineated as a Mendelian entity by Song et al. in 1999 and is now formally recognized by the WHO 5th‑edition and ICC classifications as a prototypic "myeloid neoplasm with germline predisposition and pre-existing platelet disorder."

Key identifiers: - OMIM disease: #601399 — Platelet Disorder, Familial, with Associated Myeloid Malignancy (FPDMM) (OMIM) - OMIM gene (RUNX1): *151385, chromosome 21q22.12 (OMIM) - HGNC: gene ID 10471 - Orphanet: ORPHA:71290 — Familial platelet disorder with associated myeloid malignancy (Orphanet) - MONDO: MONDO:0100083 - ClinVar condition record example: NM_001754.5(RUNX1):c.602G>A (p.Arg201Gln) AND "Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1" (ClinVar) - NCI PDQ summary exists as a dedicated cancer genetics resource: "RUNX1‑Familial Platelet Disorder (PDQ®)" (NCBI Bookshelf NBK598339)

Synonyms: FPD/AML; familial platelet disorder with propensity to AML; thrombocytopenia 2 (historic); familial platelet syndrome with predisposition to acute myelogenous leukemia (Orphanet synonym).

Evidence basis: This entry is derived almost entirely from aggregated disease-level resources — GeneReviews, OMIM, Orphanet, WHO/ICC classification, ClinGen curation, and case-series/cohort literature (~200 families and >130 individuals reported cumulatively) — rather than from a single large EHR population, reflecting genuine rarity.

2. Etiology

Primary cause: Heterozygous germline loss-of-function or dominant-negative pathogenic variants in RUNX1 (encoding RUNX1/AML1/CBFA2, a core-binding transcription factor that heterodimerizes with CBFβ). This is a purely monogenic, highly penetrant-for-phenotype/variably-penetrant-for-malignancy Mendelian disorder — there is no known environmental or infectious primary cause of the germline predisposition itself.

Genetic risk factors: - Causal variants: ~80% are detected by sequence analysis — missense, nonsense, splice-site variants, and small indels, concentrated in the Runt homology domain (RHD), which mediates both DNA binding and CBFβ heterodimerization; variants also occur in the transactivation domain (TAD) and at splice sites. ~20% are gross deletions/duplications (including whole-gene deletion) detected by dosage analysis (GeneReviews). - Mechanistic classes: frameshift and large deletions → haploinsufficiency (loss-of-function); some missense/nonsense variants in the RHD act as dominant-negative alleles that impair DNA binding/transactivation of the wild-type allele product, generally associated with a more severe phenotype than simple haploinsufficiency (Simon et al., Leukemia 2020, functional classification of RUNX1 variants). - Second-hit/somatic modifier variants driving progression to malignancy: somatic pathogenic variants in ASXL1, CBL, CDC25C, FLT3, PHF6, SRSF2, and WT1, plus loss of the remaining wild-type RUNX1 allele (often via acquired uniparental disomy of chromosome 21, or biallelic RUNX1 inactivation). Age-related clonal hematopoiesis genes — TET2 and DNMT3A — are the most frequently observed secondary somatic variants in surveillance cohorts and are thought to mark early clonal evolution rather than transformation itself (PMC9320507, "Beyond Pathogenic RUNX1 Germline Variants"). - Genotype–severity correlation: functional class (null/haploinsufficient vs. dominant-negative) and possibly variant location within RHD vs. TAD influence leukemogenic risk, though penetrance remains incompletely predictable from genotype alone.

Environmental/lifestyle risk factors: Not disease-causing, but GeneReviews management guidance flags obesity and chemical/genotoxic exposure (e.g., unnecessary ionizing radiation, tobacco smoke) as plausible modifiers that may increase malignancy risk in carriers, and recommends avoidance as a precaution rather than as an evidence-graded finding.

Protective factors: No validated genetic or environmental protective factors are established in the literature; this remains an evidence gap.

Gene–environment interaction: No specific GxE interaction has been characterized; the dominant model is a two-(or multi-)hit somatic evolution model layered on a haploinsufficient/dominant-negative germline background, analogous to but mechanistically distinct from classical tumor-suppressor two-hit kinetics (biallelic inactivation is one but not the only path to leukemic transformation here — cooperating epigenetic-regulator mutations are more common).

3. Phenotypes

Bleeding/platelet phenotype (present in ~90% of affected individuals): - Thrombocytopenia: typically mild-to-moderate (platelet counts 50–150 × 10⁹/L); a subset have normal counts (>150 × 10⁹/L) despite qualitative dysfunction. - Qualitative platelet dysfunction exceeding what platelet count alone predicts: abnormal aggregation (blunted response to arachidonic acid, collagen, ADP, epinephrine), abnormal secretion, and platelet dense-granule and/or alpha-granule storage pool deficiency on electron microscopy in roughly half of tested patients. - Clinical bleeding: easy bruising without trauma, mucocutaneous bleeding, gum bleeding, menorrhagia, peri-/post-partum hemorrhage, excess surgical/dental bleeding; 20–25% require platelet transfusion or antifibrinolytics for hemostatic challenges (GeneReviews). - Suggested HPO terms: HP:0001873 (Thrombocytopenia), HP:0011869 (Abnormal platelet function), HP:0000978 (Bruising susceptibility), HP:0000979 (Purpura), HP:0000032 (Dysmenorrhea/Menorrhagia — HP:0000132 Menorrhagia), HP:0011024 (Abnormality of the digestive system — for GI bleeding as needed).

Hematologic malignancy phenotype: - Lifetime risk of hematologic malignancy: ~35–50% (frequently cited as ~44% by age 50) (HemaSphere 2025, Ernst et al.; natural history study, Blood 2023, PMID 37738626). - Median age of malignancy onset: 33 years, though pediatric- and later adult-onset cases both occur. - Predominant malignancies: AML and MDS are the most common initial presentations (AML in ~26.9%, MDS in ~13.4% of malignancy presentations in cohort data); T‑ and B‑cell ALL and lymphomas occur in a minority of families (~25% of families report a lymphoid malignancy at some point). - HPO terms: HP:0004808 (Myelodysplasia), HP:0004808-adjacent HP:0002488 (Acute myeloid leukemia would map via MONDO/HP disease terms rather than phenotype terms — flag for curation), HP:0005506 (Leukemia, general).

Skin manifestations: eczema and/or psoriasis reported in ~50% of families, typically childhood-onset and mild, managed topically (HP:0000964 Eczema; HP:0003765 Psoriasiform dermatitis / HP:0003765).

Bone marrow histopathology: hypocellular-to-normocellular marrow; atypical, non-dysplastic megakaryocytes — small, hypolobated, scant cytoplasm — a described feature distinguishing pre-leukemic RUNX1-FPDMM marrow from classic MDS dysplasia (Haematologica, bone marrow pathology in FPDMM).

Quality of life: No dedicated EQ-5D/SF-36 disease-specific data were identified in the literature; qualitative burden is described via chronic bleeding-diathesis management, psychosocial impact of unexplained bruising (including risk of misattributed child-abuse concern, explicitly flagged in GeneReviews management guidance), and the substantial anxiety burden of lifelong malignancy surveillance — this is a genuine evidence gap rather than an omission.

4. Genetic/Molecular Information

Causal gene: RUNX1 (RUNX Family Transcription Factor 1; previously AML1/CBFA2), HGNC:10471, chromosome 21q22.12, 12 exons.

Protein domains: - Runt homology domain (RHD), exons 2–4, ~128 amino acids: mediates sequence-specific DNA binding (5′-PyGPyGGTPy-3′ consensus) and heterodimerization with CBFβ, which stabilizes RHD–DNA contacts. Most pathogenic missense/nonsense variants cluster here (ScienceDirect structural review; GeneCards). - Transactivation domain (TAD), C-terminal/exon 6 region: required for transcriptional activation and contains a nuclear matrix-targeting signal essential for in vivo function.

Variant spectrum and classification (ACMG/AMP-graded): - Missense, nonsense, frameshift, splice-site variants, and small indels (~80% of pathogenic findings by sequence analysis) plus gross deletions/duplications, including whole-gene deletion (~20%, detected by CNV/dosage analysis). - ClinVar carries numerous graded examples, e.g., NM_001754.5(RUNX1):c.602G>A (p.Arg201Gln) and c.1283dup (p.Leu429fs) associated with "Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1." - Functional classification (Simon et al., Leukemia 2021) stratifies variants by transcriptional activity into loss-of-function/haploinsufficient vs. dominant-negative classes, which correlates with clinical severity (Nature/Leukemia). - gnomAD/population databases: pathogenic RUNX1-FPDMM variants are essentially absent or present only as extreme rarities in the general population given the phenotype's severity and rarity (~200 families reported worldwide); this is consistent with dominant, disease-causing rarity rather than a common-variant susceptibility architecture.

Somatic vs. germline distinction (critical for testing): - Somatic RUNX1 mutations are common in sporadic AML/MDS and in breast cancer, unrelated to germline predisposition; variant allele fraction <40% in tumor tissue is a practical (not absolute) heuristic suggesting a somatic rather than constitutional origin (GeneReviews). - Critical technical pitfall: acquired loss of heterozygosity via uniparental disomy of chromosome 21 can occur in hematopoietic tissue of carriers, causing false-negative germline testing results from blood/marrow DNA. GeneReviews explicitly recommends cultured skin fibroblasts (buccal samples as a fallback, with risk of blood contamination) for definitive germline testing, and states testing during active malignancy is unreliable because ~10% of sporadic hematologic malignancy cases carry (typically somatic) RUNX1 variants incidentally.

Somatic "second hits" driving leukemic transformation: most frequently affect epigenetic regulators TET2 and DNMT3A (age-related clonal hematopoiesis genes, seen on longitudinal surveillance), plus cooperating driver mutations in ASXL1, CBL, CDC25C, FLT3, PHF6, SRSF2, WT1, and biallelic RUNX1 loss (PMC9320507; Blood Advances 2024, genomic landscape). A 2025 focused study (PMC11919008) further characterizes germline RUNX1 variant frequency and function specifically within diagnosed myeloid neoplasm cohorts.

Modifier genes: No validated independent modifier locus beyond the acquired somatic events above; functional variant class (haploinsufficient vs. dominant-negative) is currently the best-supported intrinsic modifier of risk.

Epigenetics: RUNX1 haploinsufficiency itself alters chromatin/transcriptional output at hematopoietic target loci (see Mechanism, below); no disease-specific DNA methylation biomarker panel is yet clinically validated, though clonal TET2/DNMT3A mutations (epigenetic regulators) are mechanistically linked to progression.

Chromosomal abnormalities: Whole-gene or partial-gene deletions of RUNX1 (21q22.12) are a recognized causal mechanism (~20% of pathogenic findings), detectable by chromosomal microarray/MLPA; distinguish from constitutional trisomy 21 (Down syndrome), which independently confers its own myeloid leukemia predisposition through a different (GATA1-related, transient abnormal myelopoiesis) mechanism — a differential that should not be conflated with RUNX1-FPDMM.

5. Environmental Information

RUNX1‑FPDMM is a purely monogenic predisposition; environmental factors modulate the timing/likelihood of second-hit malignant transformation rather than causing the underlying platelet/predisposition phenotype.

• Chemical/toxin exposure: GeneReviews management guidance advises avoidance of unnecessary genotoxic exposures (radiation, tobacco smoke, occupational chemical exposures) as a precautionary measure to reduce mutagenic pressure on the already-haploinsufficient hematopoietic compartment, though this is expert consensus rather than a quantified epidemiologic effect size.
• Lifestyle factors: Obesity is flagged as a possible malignancy-risk modifier; NSAIDs, antiplatelet agents, and statins are specifically listed as agents to avoid because they can unmask or worsen the underlying qualitative platelet defect (bleeding risk, not malignancy risk).
• Infectious agents: No infectious trigger has been identified or is biologically plausible as a primary driver; this is not an infection-associated disease.

6. Mechanism / Pathophysiology

Causal chain (numbered, from germline lesion to clinical manifestations)

1. A heterozygous germline pathogenic variant in RUNX1 reduces functional RUNX1 dosage in hematopoietic stem/progenitor cells — either by simple loss-of-function/haploinsufficiency (frameshift, nonsense, deletion) or by a dominant-negative mechanism in which a mutant RHD protein still binds CBFβ/DNA but fails to transactivate target genes, poisoning the wild-type allele's output (Simon et al. 2021).
2. Reduced RUNX1:CBFβ transcriptional activity impairs megakaryocyte maturation and polyploidization, demonstrated directly in a rhesus macaque RUNX1-FPDMM model in which CD34+ HSPCs showed "impaired in vitro megakaryocytic differentiation, with a striking defect in polyploidization" and marrow "megakaryocytic dysplasia similar to human FPDMM" (Blood 2023, DOI 10.1182/blood.2022018193, PMID 36322931).
3. This leads to quantitative thrombocytopenia (reduced platelet output from dysplastic megakaryocytes) — the clinical bleeding phenotype's first component.
4. In parallel, RUNX1 haploinsufficiency directly downregulates specific platelet-granule biogenesis genes, most notably PLDN (pallidin), a subunit of the BLOC-1 complex required for dense-granule biogenesis: "PLDN is a direct transcriptional target of RUNX1, and its decreased expression constitutes a mechanism for the platelet dense granule deficiency in patients with RUNX1 haplodeficiency" (ASH abstract, PLDN mechanism). Additional dysregulated RUNX1 targets include RAB27B, MYL9, ALOX12, PF4, PRKCQ (PKC‑θ), RAB1B, TREML1, ITGA2, MPL, NFE2, NOTCH4, and A4GALT.
5. Loss of these targets produces qualitative platelet dysfunction: decreased aggregation, decreased secretion (dense- and alpha-granule storage pool deficiency, plus a broader defect in acid-hydrolase/lysosomal secretion independent of granule content — Haemophilia 2017, Rao et al.), reduced myosin light chain/pleckstrin phosphorylation, reduced 12-HETE production, and impaired αIIbβ3 activation (J Thromb Haemost 2014, Glembotsky et al., PMID 24606315). This qualitative defect explains why bleeding severity exceeds what platelet count alone predicts.
6. Independently, chronically reduced RUNX1 dosage in hematopoietic stem cells creates a pre-leukemic clonal state: the residual (haploinsufficient or dominant-negative-poisoned) HSC/progenitor pool is intrinsically primed for clonal drift. In the rhesus macaque model, RUNX1-edited HSPC clones progressively expanded relative to control-edited clones over time even without additional mutations — direct in vivo evidence that reduced RUNX1 dosage alone confers a clonal competitive advantage.
7. Over years, this primed clone acquires cooperating somatic ("second-hit") mutations — most commonly in the epigenetic regulators TET2 and DNMT3A (age-related clonal hematopoiesis genes), and less commonly in ASXL1, CBL, CDC25C, FLT3, PHF6, SRSF2, WT1, or biallelic RUNX1 inactivation (frequently via acquired uniparental disomy of chromosome 21) (Genomic Landscape studies; Blood Advances 2024).
8. Clonal outgrowth with these cooperating lesions leads to myelodysplastic syndrome — marrow dysplasia and cytopenias — which in a substantial fraction of patients progresses to overt acute myeloid leukemia (or, less commonly, T-/B-lymphoblastic leukemia/lymphoma via a still less well-characterized branch of the same predisposed hematopoietic compartment).
9. Because malignant transformation depends on this multi-hit somatic evolution layered on a chronically haploinsufficient stem cell compartment, RUNX1‑FPDMM-associated leukemia is not curable with chemotherapy alone — the germline lesion persists in every surviving HSC — and allogeneic hematopoietic stem cell transplantation is the only curative modality, a direct mechanistic consequence of step 1 rather than merely a treatment-guideline statement.

Branch point (step 9, inferred/translationally important): the rhesus macaque data specifically predict that autologous gene-correction/gene-therapy approaches will be mechanistically challenged, because corrected (wild-type-restored) HSPCs did not show a competitive advantage over RUNX1-heterozygous mutant HSPCs long-term in the primate model — i.e., simply correcting a fraction of stem cells may not be sufficient to outcompete the pre-existing mutant clone, an inference explicitly flagged by the study authors as a challenge for curative gene therapy design (PMID 36322931).

Molecular pathways, cellular processes, and profiling

• Pathway: RUNX1:CBFβ core-binding-factor transcriptional network governing megakaryopoiesis and myeloid/lymphoid differentiation (KEGG/Reactome: "Transcriptional regulation by RUNX1," Reactome R-HSA-8878171).
• Cellular processes: megakaryocyte differentiation and polyploidization (defective); platelet granule biogenesis and secretion (defective); HSC self-renewal/clonal fitness (dysregulated, pro-clonal).
• Suggested GO terms: GO:0030220 (platelet formation), GO:0007596 (blood coagulation), GO:0045055 (regulated exocytosis — granule secretion), GO:0030220-adjacent GO:0061564-type differentiation terms, GO:0004725-unrelated (not applicable here — RUNX1 is a transcription factor, not a phosphatase); more precisely GO:0043433 (negative regulation of DNA-binding transcription factor activity, for dominant-negative variant mechanism), GO:0030099 (myeloid cell differentiation).
• Suggested CL terms: CL:0000556 (megakaryocyte), CL:0000767 (basophil — not primary), CL:0000037 (hematopoietic stem cell), CL:0000234 (phagocyte — not primary); most central: CL:0000556 megakaryocyte and CL:0000037 HSC.
• Molecular profiling: No large-scale disease-dedicated transcriptomic/proteomic/metabolomic public dataset was identified beyond targeted RUNX1-target-gene expression studies (PLDN, RAB27B, MYL9, etc.) and the genomic-landscape (targeted/whole-exome) sequencing cohorts cited above; single-cell and spatial transcriptomic characterization of RUNX1‑FPDMM marrow specifically is an evidence gap relative to sporadic AML/MDS single-cell atlases.
• Functional genomics screens: CRISPR-based functional variant classification (Simon et al. 2021) is the primary functional-genomics dataset directly informing pathogenicity/severity stratification for this disease.

7. Anatomical Structures Affected

• Primary organ/system: Bone marrow (hematopoietic system) — megakaryocyte lineage primarily, with secondary myeloid (and occasionally lymphoid) lineage involvement upon transformation.
• Secondary involvement: Skin (eczema/psoriasis in ~50% of families); systemic bleeding manifestations (mucosal surfaces — gingiva, uterus/reproductive tract — menorrhagia, peripartum hemorrhage; GI tract in severe bleeding).
• Tissue/cell level: Megakaryocytes (CL:0000556) — small, hypolobated, scant-cytoplasm, non-dysplastic-appearing but functionally abnormal; hematopoietic stem/progenitor cells (CL:0000037); platelets (anucleate cell fragments) with dense-granule (lysosome-related organelle) and alpha-granule defects.
• Subcellular level: Platelet dense granules and alpha granules (GO Cellular Component: GO:0042582 azurophil granule-adjacent; specifically GO:0031091 platelet alpha granule, and the platelet dense granule / delta granule compartment linked to BLOC-1 complex dysfunction via PLDN loss); nucleus (RUNX1 is a nuclear transcription factor, GO:0005634).
• Localization/laterality: Systemic/hematologic — not applicable to lateralization; marrow involvement is diffuse/multifocal rather than localized.
• UBERON suggestions: UBERON:0002371 (bone marrow), UBERON:0001977 (platelet — note: UBERON models platelet as a cell type via CL, not strictly organ), UBERON:0002097 (skin of body) for the dermatologic manifestations.

8. Temporal Development

• Onset of platelet/bleeding phenotype: Often present from birth/early childhood (congenital thrombocytopenia recognized incidentally or via bleeding symptoms), though it may go unrecognized for years given mild severity.
• Onset of malignancy: Highly variable — pediatric AML/MDS cases occur, but median age of malignancy onset is 33 years, spanning a wide range into later adulthood; this is a lifelong, not time-limited, risk window.
• Progression pattern: Not a single linear staged disease — better modeled as (a) a stable baseline phenotype (thrombocytopenia/bleeding, present from an early age and generally non-progressive in isolation) with (b) a superimposed, stochastic clonal-evolution risk that can manifest at any point in life as MDS (often insidious, detected via cytopenia surveillance) which may then progress to overt AML. Some patients transform directly to AML without a preceding clinically apparent MDS phase.
• Remission/course: MDS/AML in this context is generally not self-limited and, per GeneReviews, "not thought to be curable with chemotherapy alone" because the germline lesion persists in the entire stem cell compartment — allogeneic HSCT is required for cure.
• Critical periods/intervention windows: The literature explicitly frames the open clinical question as when (if ever) to intervene preemptively with HSCT versus continued surveillance — a 2025 paper proposes a formal "shared decision-making framework" for exactly this question, underscoring that no consensus critical intervention window yet exists (PMID 41924923, preemptive HSCT decision framework).

9. Inheritance and Population

• Inheritance pattern: Autosomal dominant. Most probands inherit the variant from an affected (sometimes subclinically affected/unrecognized) parent; de novo occurrence is reported but its proportion is not firmly established in the literature.
• Penetrance: Incomplete and variable. GeneReviews states penetrance is formally "unknown"; commonly cited figures are a 35–50% lifetime risk of hematologic malignancy (frequently summarized as ~44% by age 50), while "a minority of individuals have no clinical or laboratory features" despite carrying a pathogenic variant — i.e., even the bleeding/platelet phenotype is not fully penetrant. RUNX1 is explicitly grouped with ANKRD26, DDX41, and ETV6 as a "variable malignant penetrance" germline predisposition syndrome, distinct from high-penetrance syndromes (Seminars in Hematology 2024 review).
• Expressivity: Highly variable, both between and within families — spectrum from asymptomatic carriage to severe transfusion-dependent bleeding and/or early leukemic transformation.
• Anticipation, mosaicism, founder effects: No genetic anticipation phenomenon (not a repeat-expansion disorder). Germline mosaicism and somatic (hematopoietic-tissue-restricted) loss of heterozygosity via uniparental disomy 21 are both specifically discussed as causes of apparent non-transmission or false-negative parental testing — this is a distinctive, clinically important feature of RUNX1-FPDMM genetic counseling (mandates non-hematopoietic tissue, e.g., cultured fibroblasts, for definitive parental/germline testing). No specific founder variant/population is described; the ~200 reported families span diverse ancestries without a dominant founder mutation.
• Consanguinity: Not a relevant risk factor for this autosomal dominant disorder.
• Epidemiology: Rare disease — approximately 200 families described worldwide in the literature to date, likely an underestimate due to underdiagnosis (mild bleeding phenotypes are easily missed, and molecular testing requires awareness of the false-negative blood-DNA pitfall). No formal population-based prevalence/incidence rate (cases per 100,000) has been established; Orphanet does not list a numeric prevalence class for ORPHA:71290 in the material reviewed. A 2023 U.S./international natural history study enrolled 214 participants including 111 patients with 39 different RUNX1 variants from 45 unrelated families — the largest prospective cohort to date (Blood 2023, PMID 37738626).
• Sex ratio / geographic distribution: No sex predilection or endemic geographic clustering has been reported; cases are described across North America, Europe, and Asia (e.g., a French pediatric cohort, PMC9928638, and a French inherited-platelet-disorder network study of nine families, PMC4845427).

10. Diagnostics

Laboratory/clinical tests: - CBC with differential (thrombocytopenia, often mild); peripheral smear (normal platelet size, distinguishing from macrothrombocytopenia syndromes like MYH9-related disease). - Platelet aggregometry: decreased response to arachidonic acid, collagen; decreased ADP/epinephrine-induced secretion. - Platelet electron microscopy: dense-granule/alpha-granule storage pool deficiency (in ~50%). - Bone marrow aspirate/biopsy: performed when constitutional symptoms or evolving cytopenias arise, looking for the atypical (non-dysplastic) small hypolobated megakaryocyte pattern versus frank MDS dysplasia.

Genetic testing (definitive diagnosis): - Gene-targeted sequence analysis of RUNX1: detects ~80% of pathogenic variants (missense/nonsense/splice/small indel). - Gene-targeted deletion/duplication (dosage) analysis: detects the remaining ~20% (exon-level or whole-gene deletions/duplications). - Multigene inherited-platelet-disorder/bone-marrow-failure panels (including RUNX1, ANKRD26, ETV6, CEBPA, DDX41, GATA2, TP53) are recommended as an efficient first-line strategy given phenotypic overlap; comprehensive exome/genome sequencing is reserved for atypical presentations. - Critical pitfall: test cultured skin fibroblasts (preferred) or buccal cells (acceptable, risk of blood contamination) rather than peripheral blood/marrow DNA for germline confirmation, because somatically acquired uniparental disomy of chromosome 21 in hematopoietic tissue can mask (false-negative) or, conversely, an incidental somatic RUNX1 variant found during active leukemia workup (~10% of unrelated hematologic malignancies) can be misinterpreted as germline without orthogonal tissue confirmation (GeneReviews). - Variant allele fraction <40% in tumor/marrow tissue is a practical (non-definitive) flag suggesting somatic rather than germline origin, pending confirmatory fibroblast testing.

Differential diagnosis (per GeneReviews): ANKRD26-related thrombocytopenia, CEBPA-associated familial AML, DDX41-associated familial MDS/AML, ETV6-related thrombocytopenia, GATA2 deficiency, Li-Fraumeni syndrome (TP53); acquired mimics include immune thrombocytopenia and drug-induced thrombocytopenia (NSAIDs, antiplatelet agents, statins). A direct 2023 Blood comparative study specifically distinguishes RUNX1, ETV6, and ANKRD26 hereditary platelet disorders, noting that although they "may initially present as similarly mild-moderate thrombocytopenia, each ... [has] distinct penetrance of HM and a different range of somatic alterations associated with malignancy development" (PMID 36626254).

Screening/surveillance for known carriers (no formal published consensus guideline exists on frequency, per literature review, though GeneReviews offers expert-consensus recommendations): - Clinical exam for constitutional symptoms (fatigue, fever, weight loss, dyspnea) every 6–12 months. - CBC with differential every 3–4 months. - Bone marrow examination triggered by new symptoms or CBC abnormalities (not routinely scheduled in the absence of a trigger). - Skin exam as needed. - A 2025 publication formally proposes a shared decision-making framework to fill the gap in consensus surveillance/timing guidance, explicitly noting "guidelines on the type of testing or frequency of surveillance have not been published" (PMID 41924923).

Prenatal/preimplantation testing: Feasible once a familial variant is identified; uptake and professional guidance vary by family/center.

11. Outcome/Prognosis

• Malignancy risk: 35–50% lifetime risk (often summarized ~44%), median onset age 33 years; AML and MDS are the dominant malignancy types (AML ~26.9%, MDS ~13.4% as initial presentation in cohort data).
• Curability: MDS/AML arising in this context is generally not curable by chemotherapy alone; allogeneic HSCT is the only curative approach, consistent with the mechanistic persistence of the germline lesion in every hematopoietic stem cell.
• Transplant outcomes: Case reports and small series describe successful allogeneic HSCT for RUNX1‑FPDMM-associated MDS/AML, including a detailed case report/literature review (PMC9800216); a dedicated 2025 HemaSphere study specifically examined AML outcomes in germline RUNX1 deficiency, characterizing disease features and transplant/treatment outcomes in this population (Ernst et al. 2025, DOI 10.1002/hem3.70057) — a key resource for prognostic detail beyond what could be fully retrieved here (site access was restricted during this research pass; recommend direct follow-up retrieval for exact survival statistics).
• Related-donor transplant caveat: because RUNX1-FPDMM is autosomal dominant with variable expressivity, potential related HSCT donors must be genetically tested and excluded as variant carriers before use as a stem cell source — a critical, disease-specific transplant-planning consideration flagged throughout the clinical literature.
• Morbidity outside of malignancy: primarily bleeding-related (transfusion dependence in a minority, procedural bleeding risk requiring premedication), and dermatologic (eczema/psoriasis, generally mild).
• Quality of life / disability data: No RUNX1-FPDMM-specific EQ-5D/SF-36/PROMIS dataset was identified; this is a notable evidence gap.
• Prognostic factors under active study: variant functional class (dominant-negative vs. haploinsufficient), clonal hematopoiesis mutation burden (TET2/DNMT3A) and its trajectory on serial sequencing, and specific cooperating driver mutations (ASXL1, CBL, FLT3, PHF6, SRSF2, WT1) at time of transformation.

12. Treatment

Pharmacotherapy for bleeding manifestations: - Desmopressin (DDAVP) — NCIT term for pharmacotherapy: NCIT:C15986 (Pharmacotherapy); specific agent term for desmopressin should be bound via CHEBI/NCIT lookup. - Antifibrinolytics: epsilon-aminocaproic acid, tranexamic acid — for surgical/dental/menstrual bleeding management. - Platelet transfusion (NCIT: transfusion-related procedure term) reserved for severe bleeding episodes or high-risk procedures.

Topical therapy for skin manifestations: emollients and topical corticosteroids for eczema/psoriasis (NCIT:C15986-adjacent topical pharmacotherapy terms).

Definitive/curative therapy for malignancy: - Allogeneic hematopoietic stem cell transplantation (NCIT:C15431, Hematopoietic Cell Transplantation) — the only curative approach for MDS/AML in this syndrome; timing (preemptive vs. at overt malignancy) remains actively debated and is the subject of a 2025 shared decision-making framework publication. - Standard AML/MDS induction chemotherapy and hypomethylating agents (e.g., azacitidine) plus venetoclax are used as in sporadic disease for bridging/cytoreduction, though not curative as monotherapy in this germline-predisposed context. Notably, RUNX1-mutated AML/MDS (germline or somatic) shows meaningful response rates to venetoclax-based regimens in broader AML/MDS cohorts (e.g., RUNX1-mutated subgroup ORR 54% in one venetoclax/azacitidine study), though these studies were not RUNX1-FPDMM-specific. - A dedicated early-phase trial specifically targets RUNX1-mutant relapsed/refractory AML/MDS with omacetaxine and venetoclax (NCT04874194) — while enrollment criteria include somatic RUNX1-mutant disease broadly rather than being exclusive to germline FPDMM, it is directly relevant to this molecular subgroup (ClinicalTrials.gov protocol; PMC12447878).

Experimental/gene-therapy landscape: - Autologous gene-correction approaches are under early preclinical investigation, but the rhesus macaque RUNX1-FPDMM model (PMID 36322931) demonstrated that corrected/control-edited HSPCs did not outcompete RUNX1-heterozygous mutant HSPCs long-term — a specific, mechanistically grounded caution that curative gene therapy for this disorder faces a nontrivial clonal-competition barrier not present in simpler monogenic HSC disorders. - A 2025 review, "Targeting RUNX1 Germline Variants: Agents Under Investigation" (Current Hematologic Malignancy Reports), catalogs emerging pharmacologic strategies aimed at clonal hematopoiesis interception in this population (Springer).

Supportive care: genetic counseling (NCIT:C15240), medical alert documentation to prevent misattributed-bleeding (child abuse) concerns, avoidance counseling for antiplatelet/NSAID medications and contact sports.

Treatment algorithm summary: (1) manage bleeding symptomatically/prophylactically; (2) structured surveillance (CBC q3–4 months, exam q6–12 months, marrow exam if triggered); (3) upon MDS/AML diagnosis, pursue allogeneic HSCT (related donors must be RUNX1-variant-tested and excluded) as the only curative modality, with cytoreductive chemotherapy/hypomethylating-agent bridging as needed; (4) no validated pharmacologic clonal-hematopoiesis-interception therapy yet exists outside clinical trials.

13. Prevention

• Primary prevention: Not applicable in the classic sense (germline variant cannot be prevented once inherited); avoidance of genotoxic exposures (radiation, smoking, occupational chemical exposure) and platelet-function-impairing medications (NSAIDs, antiplatelet agents, statins) is recommended as a precautionary risk-reduction measure for both bleeding and, speculatively, malignancy risk.
• Secondary prevention (early detection): Structured hematologic surveillance in known carriers (as above) to catch MDS/pre-AML changes at the earliest, most treatable stage; this is the closest analog to a "screening program" for this disorder, though it is expert-consensus rather than a formally validated USPSTF/CDC-style program.
• Genetic screening: Cascade testing of at-risk relatives once a familial variant is identified is explicitly recommended (using non-hematopoietic tissue for definitive results) to identify asymptomatic carriers who need surveillance; prenatal and preimplantation genetic testing are technically available once the familial variant is known, with uptake being a family-preference-driven decision.
• Genetic counseling: Central to management — communicating the 50% transmission risk to offspring, the variable/incomplete penetrance (a minority of carriers are entirely asymptomatic), the germline-mosaicism/loss-of-heterozygosity testing pitfalls, and reproductive options.
• Tertiary prevention: Once malignancy develops, allogeneic HSCT is pursued specifically to prevent relapse/progression, given the ineffectiveness of chemotherapy alone at achieving durable remission in this predisposed stem cell compartment.
• Immunization/prophylaxis/public health measures: Not applicable — this is not an infectious or environmentally-driven condition amenable to vaccination or public-health-level intervention.

14. Other Species / Natural Disease

• Taxonomy of model use: Macaca mulatta (rhesus macaque, NCBITaxon:9544), Danio rerio (zebrafish, NCBITaxon:7955), Mus musculus (mouse, NCBITaxon:10090) are the principal non-human systems used — this is a research-model landscape rather than a naturally occurring veterinary disease.
• Naturally occurring veterinary disease: No OMIA entry or naturally occurring companion-animal/livestock phenocopy of RUNX1-FPDMM specific to a germline RUNX1 variant was identified in this search; this is an evidence gap (worth a targeted OMIA search if precise veterinary comparanda are needed) rather than a confirmed absence.
• Orthologous gene: Runx1 is highly conserved across vertebrates (mouse, zebrafish orthologs confirmed functionally essential for definitive hematopoiesis; NCBI Gene mouse Runx1 and zebrafish runx1 entries exist), underlying the strong translational relevance of the animal models below despite no known spontaneous animal phenocopy.
• Comparative pathology: Complete constitutional Runx1 knockout is embryonic lethal in mouse (loss of all definitive hematopoiesis, death ~E12.5–13); this establishes RUNX1 as absolutely essential for HSC emergence from hemogenic endothelium, and by extension explains why FPDMM arises from partial (heterozygous) rather than complete loss of function — complete biallelic loss is not compatible with a viable postnatal disease state, reinforcing the haploinsufficiency/dominant-negative disease model in humans.
• Zoonotic potential: None; not applicable.

15. Model Organisms

• Mouse models: Multiple germline loss-of-function Runx1-FPD mouse models exist. One key model demonstrated "hematopoietic cell autonomous disruption of hematopoiesis in a germline loss-of-function mouse model of RUNX1-FPD" (PMID 36741355). Compound-mutant mice (RUNX1-FPD background plus a cooperating secondary mutation) developed MDS/AML with ~30% penetrance, directly modeling the two-hit progression described in the human mechanism section (2023 ASH/EHA presentation, ScienceDirect abstract). These models are explicitly being used and shared with the field to test candidate drugs for delaying/preventing/reversing clonal HSC expansion.
• Complete Runx1 knockout mice are embryonic lethal (E13), confirming RUNX1's essential, non-redundant role in definitive HSC emergence — relevant context for why FPDMM models use partial/heterozygous or hematopoietic-cell-conditional alleles rather than full knockouts.
• Zebrafish models: Zebrafish runx1 knockout embryos are transiently "bloodless" during embryonic definitive hematopoiesis but, unexpectedly, recover and develop multi-lineage hematopoiesis as adults, revealing a RUNX1-independent, developmental-stage-specific compensatory hematopoietic program not present in mammals — an important species-translation caveat (a candidate HUMAN_MODEL_MISMATCH-type consideration for curation: complete loss is tolerated long-term in zebrafish but embryonic-lethal in mouse and pathogenic-but-viable as heterozygous loss in humans) (Blood, "Development of RUNX1-Independent Hematopoiesis in Three Zebrafish runx1-KO Models"). CBFβ and RUNX1 were also shown to be required at two distinct steps of zebrafish HSC development, refining the developmental-timing model of RUNX1 dependency (Blood 2014, PMID-linked study).
• Non-human primate model (highest translational fidelity): The rhesus macaque RUNX1-FPDMM competitive-repopulation model (CRISPR/Cas9 NHEJ editing of autologous HSPCs, transplanted as a mixed RUNX1-edited/AAVS1-control-edited population) is the most human-relevant model to date. It recapitulates megakaryocytic dysplasia and the polyploidization defect seen in human marrow, and demonstrates in vivo clonal expansion of RUNX1-mutant HSPCs relative to controls — directly supporting the pre-leukemic clonal-priming mechanism proposed for human disease, and yielding the specific translational caution about gene-therapy feasibility described above (Blood 2023, PMID 36322931, DOI 10.1182/blood.2022018193).
• Model limitations: No model fully recapitulates the human bleeding-diathesis/dense-granule-deficiency phenotype with clinical-grade fidelity alongside the full malignancy-progression timeline in a single system; the mouse compound-mutant models best capture leukemic progression kinetics (30% penetrance), while the macaque model best captures the megakaryocyte/HSC-fitness phenotype, and zebrafish models are primarily informative for developmental RUNX1 dependency rather than adult disease modeling.
• Resources: Models described in the cited primary literature are stated to be shared with investigators (mouse model, per RUNX1 Research Program communications); no dedicated public repository (JAX/IMSR/ZFIN stock number) was confirmed in this search pass and should be verified directly with the originating labs (RUNX1 Research Program, runx1-fpd.org) before citing a specific stock/strain identifier.

Summary of Notable Evidence Gaps (flagged rather than smoothed over)

1. No consensus surveillance or preemptive-HSCT timing guideline exists in the literature to date; a 2025 shared decision-making framework is the closest current answer (PMID 41924923).
2. No formal population-based prevalence/incidence rate (cases per 100,000) is established — only "≈200 families reported."
3. No disease-specific QoL instrument data (EQ-5D/SF-36/PROMIS) were located.
4. De novo variant proportion is not precisely quantified in current GeneReviews text.
5. No confirmed naturally occurring veterinary/OMIA phenocopy was found — absence is reported as unconfirmed rather than definitively ruled out.
6. The HemaSphere 2025 AML-outcomes paper (Ernst et al.) could not be fully retrieved (403 error) in this session; its precise survival/outcome statistics should be verified by direct PMID/DOI lookup (DOI: 10.1002/hem3.70057) before being cited with specific numbers in a curated entry.

Full Source List

• GeneReviews: RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies (updated Jan 2024/2025)
• OMIM #601399 FPDMM; OMIM *151385 RUNX1
• Orphanet ORPHA:71290
• NCI PDQ: RUNX1-Familial Platelet Disorder
• NORD: FPDMM
• Ernst et al. 2025, HemaSphere, "Disease characteristics and outcomes of AML in germline RUNX1 deficiency" — DOI 10.1002/hem3.70057
• Natural history study, Blood 2023 — PMID 37738626, DOI 10.1182/blood.2023019746 — link
• Rhesus macaque model, Blood 2023 — PMID 36322931, DOI 10.1182/blood.2022018193 — link
• Simon et al., functional classification of RUNX1 variants, Leukemia 2021 — link
• "Beyond Pathogenic RUNX1 Germline Variants" — PMC9320507
• Genomic landscape, Blood Advances 2024 — link
• Hereditary platelet disorders (RUNX1/ETV6/ANKRD26), Blood 2023 — PMID 36626254 — link
• Glembotsky et al., platelet function mechanism, J Thromb Haemost 2014 — PMID 24606315
• PLDN/pallidin mechanism, ASH abstract — link
• Bone marrow histopathology, Haematologica — link
• Preemptive HSCT shared decision-making framework — PMID 41924923
• Zebrafish runx1-KO models, Blood — link
• CBFβ/RUNX1 zebrafish HSC steps, Blood 2014 — link
• Hematopoietic-cell-autonomous mouse model — PMID 36741355
• Germline predisposition to myeloid neoplasms review, Seminars in Hematology 2024 — link
• Omacetaxine + venetoclax RUNX1-mutant AML/MDS trial (NCT04874194) — protocol; PMC12447878
• "Targeting RUNX1 Germline Variants: Agents Under Investigation," Curr Hematol Malig Rep 2025 — link

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:41924923 (abstract only): "guidelines on the type of testing or frequency of surveillance have not been published"
• closest text in source: "We introduce a shared decision-making framework designed to support individuals with RUNX1-FPD, their families, and their multidisciplinary clinical teams in evaluating whether and when to pursue preemptive HSCT versus continued surveillance"
• DOI:10.1002/hem3.70057 (abstract only): "Disease characteristics and outcomes of AML in germline RUNX1 deficiency"
• closest text in source: "AbstractFamilial Platelet Disorder with associated Myeloid Malignancy (FPDMM, FPD/AML, RUNX1‐FPD), caused by monoallelic deleterious germline RUNX1 variants, is characterized by bleeding diathesis and predisposition for hematologic malignancies, particularly myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0002488 (1 mention) - the report calls it "Acute myeloid leukemia would map via MONDO/HP disease terms rather than phenotype terms — flag for curation"; HP calls it Acute leukemia
• HP:0005506 (1 mention) - the report calls it "Leukemia, general"; HP calls it Chronic myelogenous leukemia
• UBERON:0001977 (1 mention) - the report calls it "platelet — note: UBERON models platelet as a cell type via CL, not strictly organ"; UBERON calls it blood serum

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0043433 (obsolete negative regulation of DNA-binding transcription factor activity) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0011024 (1 mention) - the report calls it "Abnormality of the digestive system — for GI bleeding as needed"; HP calls it Abnormality of the gastrointestinal tract
• HP:0004808 (2 mentions) - the report calls it "Myelodysplasia"; HP calls it Acute myeloid leukemia, and lists "Acute myeloid leukaemia" among its other names
• GO:0045055 (1 mention) - the report calls it "regulated exocytosis — granule secretion"; GO calls it regulated exocytosis
• GO:0043433 (1 mention) - the report calls it "negative regulation of DNA-binding transcription factor activity, for dominant-negative variant mechanism"; GO calls it obsolete negative regulation of DNA-binding transcription factor activity, and lists "negative regulation of DNA binding transcription factor activity" among its other names
• CL:0000556 (3 mentions) - the report calls it "megakaryocyte", "Tissue/cell level: Megakaryocytes"; CL calls it megakaryocyte**
• CL:0000767 (1 mention) - the report calls it "basophil — not primary"; CL calls it basophil
• CL:0000234 (1 mention) - the report calls it "phagocyte — not primary"; CL calls it phagocyte

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• CL:0000556 - called "megakaryocyte", "Tissue/cell level:** Megakaryocytes"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.